Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer

Introduction: Increasing evidence suggests that consolidation durvalumab confers limited benefits for patients with stage III EGFR-mutated NSCLC. Induction or maintenance EGFR tyrosine kinase inhibitors (TKIs) added to concurrent chemoradiotherapy (CRT) may optimize definitive treatment, but there a...

Full description

Bibliographic Details

Published in:	Cancer Treatment and Research Communications
Main Authors:	Jacqueline V. Aredo, Heather A. Wakelee, Angela Bik-Yu Hui, Sukhmani K. Padda, Nitin D. Joshi, H. Henry Guo, Aadel Chaudhuri, Maximilian Diehn, Billy W. Loo, Jr., Joel W. Neal
Format:	Article
Language:	English
Published:	Elsevier 2022-01-01
Subjects:	EGFR mutation Concurrent chemoradiotherapy Osimertinib Erlotinib Induction EGFR TKI
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468294222001502